Table 2.
Studies with CBD with Patients with Psychotic Symptoms (Adapted)69
| Assessment | Oral CBD administration | Total number of study participants | Main findings |
|---|---|---|---|
| BPRS (brief psychiatric rating scale) | Up to 1500 mg/day for 26 days | 1 | Improvement of symptomatology, no side effects |
| BPRS | Up to 1280 mg/day for 4 weeks | 3 | Mild improvement of symptomatology of 1 patient, no side effects |
| BPRS, Parkinson Psychosis Questionnaire (PPQ) | Up to 600 mg/day for 4 weeks | 6 | Improvement of symptomatology, no side effects |
| Stroop Color Word Test, BPRS, PANSS (positive and negative symptom scale) | Single doses of 300 or 600 mg | 28 | Performance after placebo and CBD 300 mg compared to CBD 600 mg; no effects on symptomatology |
| BPRS, PANSS | Up to 800 mg/day for 4 weeks | 39 | CBD as effective as amisulpride in terms of improvement of symptomatology; CBD displayed superior side effect profile |